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Abstract
Purpose—Return of individual research results from genomic studies is a hotly debated ethical
issue in genomic research. However, the perspective of key stakeholders—Institutional Review
Board (IRB) reviewers—has been missing from this dialogue. This study explores the positions
and experiences of IRB members and staff regarding this issue.
Methods—In depth interviews with 31 IRB professionals at six sites across the United States.
Results—IRB professionals agreed that research results should be returned to research
participants when results are medically actionable but only if the participants wanted to know the
result. Many respondents expected researchers to address the issue of return of results (ROR) in
the IRB application and informed-consent document. Many respondents were not comfortable
with their expertise in genomics research, and only a few described actual experiences in
addressing ROR. Although participants agreed that guidelines would be helpful, most were
reticent to develop them in isolation. Even where IRB guidance exists (e.g., CLIA lab certification
required for return), in practice, the guidance has been overruled to allow return (e.g., no CLIA lab
performs the assay).
Conclusion—An IRB-researcher partnership is needed to help inform responsible and feasible
institutional approaches to returning research results.
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INTRODUCTION
One of the most common ethical dilemmas in human genomic research is the challenge of
deciding whether to tell participants what researchers discover about individuals’
genomes.1-5 With the accelerating use of genomic analysis techniques, researchers are
increasingly encountering research results that are associated with potential as well as
known health implications. Although this challenge was anticipated in the literature since
early in the Human Genome Project,6 and a robust effort has been devoted to developing
recommendations and models to address this issue,1, 4, 5, 7-20 currently no national policy
exists to guide researchers, research participants or Institutional Review Board (IRB)
professionals. In practice, decisions related to return of results (ROR) are left to local
institutions.
The 2007 National Institutes of Health (NIH) GWAS Data-Sharing Policy suggests that
“contributing institutions and IRBs may wish to establish policies to determine when it is
appropriate to return individual findings from research studies.”21 IRBs are a logical place
for researchers to look for guidance on deciding whether and how to return research results,
since they are charged with protecting the rights and interests of research participants in the
review and approval of human genomic research protocols. Studies show that researchers
identify IRBs as the relevant authority in this regard,22 and that IRB Chairs and human
subjects professionals recognize that returning results is an important human subjects
research issue,18, 23 yet few studies have analyzed how IRB professionals are thinking about
this issue and what they are doing to address it.
If, in the absence of federal public policy guidance, IRBs are to develop a shared capacity to
help investigators address the challenge of returning results, it will be important to
understand their baseline experiences and local practices. The purpose of the current study
was to begin that assessment by analyzing IRB perspectives and approaches for returning
research results of genomic studies to individual research participants. The study is part of a
larger effort to evaluate experiences and views of IRBs and genomic researchers in the
review and conduct of genetic and genomic research.23, 24
MATERIALS AND METHODS
Population
We invited IRB members and staff at four major academic centers and two research
hospitals across the U.S. to participate in semi-structured interviews. We first contacted the
IRB director at each site to identify the most appropriate method for recruiting IRB
professionals. At the request of several sites to protect the respondents, neither site name nor
position on the IRB (e.g., Chair, co-Chair) is reported in this paper. Individuals who had
been active members of an IRB within the last two years and whose job responsibilities
included the review of biomedical research protocols were eligible to participate.
Approach and Analysis
Focus groups conducted at two of the six sites informed the development of an interview
guide that was used in subsequent one-on-one semi-structured interviews. These one- time
interviews were conducted mainly in person (and occasionally by phone) and lasted 45-60
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minutes. Due to the time limit, not every interview included all questions in the guide, but
all respondents answered the following questions: “Do you think results of genetic or
genomic research studies should be provided to individual participants? Why or why not?
Under what conditions should research results be returned?” These questions also gave
respondents an opportunity to describe their experiences addressing this issue in their IRB.
All interviews were audio-recorded and transcribed, and assigned a study identification
code. No personal identifiers were collected and no master list was maintained that could
link the code to the respondent. Verbal consent was obtained from all but one site that
required written consent.
We followed criteria established for qualitative methods to assure the rigor and
trustworthiness of data collection, coding and analysis procedures.25-27 Briefly, transcripts
were first checked for accuracy and the interview text was then analyzed for content related
to return of research results. After development of a coding schema by the study team,
coding was performed independently by two analysts and compared for agreement. Areas of
disagreement were resolved through discussion, and on occasion, by a third coder. The
ATLAS.ti software program was used to aid in indexing, searching and retrieving sections
of data related to ROR. In-depth analysis of the coded data was conducted by team review
through an iterative process of analytic induction to document and interpret themes and
patterns using a grounded theory approach.28-30 Responses by IRB members and staff were
initially reviewed separately and then compared. Since we did not observe differences in
perspectives between the two groups, all responses in this paper are reported as one group of
IRB professionals.
We also collected demographic information, including sex, age, education, profession, years
of experience with the IRB, average number of genetic or genomic research studies
reviewed per month, and experience conducting or participating in genetic or genomic
research.
This study was reviewed and approved by the IRBs at each of the six sites.
RESULTS
Demographics of Respondents
Thirty-one individuals comprising 24 IRB members and 7 staff participated in the
interviews, 18 of whom were female. All but one respondent reported experience reviewing
genetic or genomic studies on a monthly basis: 20 reported reviewing an average of 1-3,
while ten reviewed more than four per month. Eleven reported a current or past role in
genetic or genomic research as co-investigator (n=5), consultant (n=3), or research staff
(n=3). IRB members represented a spectrum of professions, including 12 health care
providers, eight researchers and one each representing law, ethics and a non-scientist
community member (one respondent did not report profession).
General perspectives on and experiences with return of individual results
These IRB professionals understood returning individual results as a perplexing issue,
describing it as “an incredibly sticky wicket” and “a big kettle of worms.” They described a
range of issues that make this topic complicated to address, including the new, fast paced,
and “rapidly evolving nature” of genomic research and, its “broad scope”, “with many
contexts.” Respondents also described their uncertainty about the reliability of the research
result, especially if the result was preliminary, and the psychological consequences of
returning results to individual research participants. The frequent and complex inter-
relationships among these issues adds to the difficulty in responding to questions about
whether individual results should be returned (see Table 1, [P3]).
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For many respondents, the interview itself offered the first opportunity to analyze the issues
associated with ROR and prompted interest in addressing this topic in their IRB: “Not sure if
the IRB has ever really thought about that [return of individual results]…but I think I’ll have
a discussion tomorrow.” Several respondents who did not have experience with returning
results anticipated that this issue was going to be more prevalent in the near future as
genetics become more routinely integrated into study designs. One respondent remarked,
“Well, a great many drug protocols now, or even device protocols, are including genetic
sub-studies.” Respondents without special expertise in genetics discussed their difficulty
evaluating the implications for research participants, especially in the absence of national
guidance (see Table 1, [P4]).
Ten respondents had either thought about this issue before (n=5) or had participated in
deciding whether to return a genetic or genomic research result (n=5). In these examples, the
IRBs’ moral responsibility in addressing this issue was often highlighted (see Table 1
[P21]). In two examples, respondents described situations they faced regarding the decision
of returning research results that were not obtained in a Clinical Laboratory Improvement
Act (CLIA) approved laboratory. In both situations the research assay was only available in
the researcher’s laboratory, and no CLIA-approved laboratory had the capacity to perform
the assay. Although their local IRB guidance indicated that only results obtained in CLIA-
approved laboratories could be returned, in both situations, this guidance was over-ruled and
the individual result was communicated to the research participant. In one of these
examples, the respondent reported that a researcher had identified several genes associated
with hyper-coagulability in an individual research participant. The IRB considered the return
of this result to have a low risk of potential harm and high anticipated benefit to the
individual and recommended returning it:
“Well, you know, if you had this knowledge, at a minimum you’d get up several
times in a five-hour flight across the country. And that may be about the extent of
what you can do, but it might keep somebody from having a stroke. And so, in that
case, the IRB, I think, felt pretty strongly that this was probably information that
should be shared.” [P21]
Regardless of level of experience or expertise, all respondents were able to describe multiple
concerns they associated with ROR, identifying many of the common issues described in the
ROR literature.1, 9, 11, 13-18, 31 Many concerns centered around the risks of returning a
research result and how the research participant would respond to and/or act on that result.
Specific concerns included the emotional and psychosocial consequences (e.g., anxiety,
worry, family discord), lifestyle changes and decisions (e.g., reproductive choices,
employment) and the potential for economic harm (e.g., as a result of losing insurance).
Positions on return of individual results
A spectrum of positions was articulated including the need to respect the research subject’s
right to know/not know research results while weighing the potential negative consequences
of returning individual results with anticipated benefit. Similar to the literature,1, 32 there
was general agreement (29/31) that preliminary, unvalidated results should not be returned,
although many respondents did not specify what they meant by preliminary or unvalidated.
Respondents discussed the importance of validating results, both analytically and clinically
(Table 1, [P15],[P23]).
Unique positions were also articulated. A respondent indicated that, based on ethical and
moral principles, research results should almost always be returned (Table 1, [P16]).
Another respondent indicated that because “it is still research”, the mutation status should be
returned, but not the interpretation of what that mutation means (e.g., the mutation may be
associated with developing a certain disease or responding to a certain drug).
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Respondents also discussed the concept of future consideration of research results and the
importance of the reliability and utility of the research result, both now and in the future.
Nearly one third (n=10) of our respondents highlighted the need to consider how a currently
uncertain research result might have implications for the future health of the research
participant, especially if the researcher maintained contact with research participants over
time and maintained a registry of research results:
“But something we try to keep in mind, and discuss sometimes with the
researchers, is that it’s true that you’re just at the research stage and what you’re
looking at right now isn’t necessarily meaningful, but…10 years down the road you
may find that information is meaningful” [P27]
Respondents also described concerns about returning individual results both related and
unrelated (unexpected or incidental) to the study aims. Overall, most respondents were
supportive of returning validated individual results if the research subject desired; however,
the provision of such results to individual research subjects was conditioned on a variety of
factors.
Conditions for return of individual results
Foremost in the dialogue on conditions for ROR was the need to respect and consider the
research subject’s desire to know or not know the research result. Some respondents also
described the need to address the implications of returning the result, especially for the
individual and/or their family (e.g., how to make sense of the result, especially if there was
no medical intervention) and, to a lesser degree, for the researcher or research community
(e.g., the infrastructure, resources and logistics that would be required to return research
results to individual research subjects). Conditions for return are part of a dynamic circle of
often interrelated and overlapping perspectives and criteria.
The most frequent conditions or criteria for returning an individual genetic research result
favored a clinical utility perspective (25/31), where results should have “clinical
significance”, “be serious or life threatening” and/or be medically actionable (e.g, a medical
intervention was available). Respondents also supported return if withholding a research
result would cause clinical or health harm, now or in the future. A personal utility
perspective, based on respect for the research subject, was also expressed. Different
justifications for this perspective included the position that returning information learned
about a research subject was a form of reciprocity for participating in the research, that
results could have personal meaning or empowerment for the research subject and could
provide the opportunity to benefit from non-medical interventions (e.g., lifestyle changes,
reproductive decision-making, investing in long term care or additional health or life
insurance, changing career path). Some conditions, such as the need to validate a result in a
“CLIA-approved laboratory” prior to return, reflected concerns from both clinical and
personal utility perspectives.
Process to manage return of results
Role of IRB in deciding whether to return a particular research result—Most
respondents indicated that a team of people should be involved in ROR decisions, including
the research investigator, scientific and other medical peers, other experts in the field, a
genetic counselor, a medical geneticist, and the individual’s treating physician. There was
limited mention of the research subject or research advocate being involved in the decision
making process, except to decide whether or not s/he wanted to know the result.
However, respondents did not agree on the specific role that the IRB should play in
decision-making. Although many indicated that the IRB should be actively involved in
Dressler et al. Page 5










making the decision, others were not comfortable with this role and suggested that the IRB
should “oversee the process” of decision-making, “I’m not sure that we have the expertise as
a body to do that [make the decision]. We can raise questions and we can bring up issues
that we think need to be addressed.” [P3] In this oversight role, the IRB would not be
involved in actual decision-making per se, but would ensure that an appropriate, ethical
process was followed for decision-making, including how the research result was
communicated to the research participant. Experience with conducting or reviewing genetic
research or years on the IRB did not seem to influence our respondent’s position on the role
the IRB should play in this process.
Approaches to managing return of results—Several respondents described
guidelines or approaches that were in place at their institution for returning results.
However, none indicated that a formal process was established to determine whether or not
to return an individual result, who should be involved in making that determination, and
how the result should be communicated to the research subject, if return was warranted.
Table 2 summarizes the approaches reported by our respondents to manage ROR. Some
respondents indicated that the ROR issue is addressed at the beginning of the study, at the
time of IRB review, especially for results related to the study aims. Researchers were
expected to indicate in the IRB application and consent document whether research results
will be returned and, if so, to offer the research subjects options for whether they wanted to
know this information. This approach is similar to recommendations from the 1999 National
Bioethics Advisory Commission.33 One respondent indicated that the researcher should
provide in the IRB application, “an honest and thought- through risk and benefit analysis [of
whether or not meaningful results might be obtained and/or should be returned].” [P4] When
ROR issues arose after initial IRB review, during the study or after study termination, many
respondents considered their deliberations to be “more problematic”, mainly because there
were no rules to follow. Many situations described at these times were consistent with
finding an incidental result, “stumbling over a medical condition”, rather than one related to
the research aims, “Especially if it’s [an incidental result] an issue that could significantly
affect the life of the subject, I think it should be disclosed.” [P30]. Respondents indicated
that situations arising after initial IRB review would be handled, “similar to other IRB
issues” on a case-by-case basis, bringing in the appropriate experts. Many respondents
voiced that an important factor in the decision making process is “whether there’s something
you can do about it. …if there’s not a step that the study participant could take to ward off
bad consequences or you know to improve his or her health, then I don’t think so.” [P12]
As indicated above, some respondents described institution policies regarding CLIA-
approved laboratory validation, “Our institution has taken a hard line, “No, you can’t [return
results] if it’s not a CLIA-approved lab” [P27]), and/or that results be communicated by a
professional trained in discussing genetic or genomic results with individuals. However, as
described earlier, sometimes these policies, (e.g., no CLIA approved laboratory could
perform an assay), were over-ruled to allow return.
Desire for Guidance
Although respondents were in favor of having some form of guidance regarding whether to
return a research result, they differed in the type of information they felt was needed. Some
wanted specific rules or regulations to follow, especially “because it still fees to me that it’s
a new area.” [P11]. Others preferred “general ground rules” to follow to preserve the
subjective and interpretive nature of IRB review, “ I get really nervous about setting
definitive [rules]. So I know everyone likes to operationalize everything, but I think that you
could potentially miss a lot” and because of the different contexts of ROR situations,
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“everything’s different, everything’s unique and everything can go one of ten different
ways.”[P1].
Some respondents suggested plans for managing ROR situations (summarized in Table 3).
This included an “optimal” approach to validating a research result and a two tiered process
for decision-making. For assay validation it was suggested that the assay be repeated with a
new sample (or second aliquot of the current sample), and ideally with a second validated
test, preferably performed in a clinical laboratory, but definitely in a CLIA-approved
laboratory. The two tiered process for decision-making included a first tier that would focus
on “judging the significance, validity and actionability of the finding” and involve the
researcher, his/her peer group, relevant clinicians and other experts in the field and the IRB.
The second tier would consider the “psychosocial implications” of returning the finding to
the research subject and would include the IRB, genetic counselors, the treating physician (if
the research subject was also a patient), psychologists and ethicists. If both tiers favored
return, the final step would include developing an appropriate process to communicate the
research finding, including asking research participants whether they wanted to know a
research finding, how the finding should be presented (e.g., in person or by phone) and by
whom (e.g., caring, skilled professional); how to determine the appropriate content and
scope of information to be communicated (e.g., probability, positive predictive value); and
the type of follow-up counseling (e.g., genetic and/or psychological) and care needed, if any.
This approach is similar to that described by Kohane et al.20 Some respondents also
recognized the requirement for an infrastructure and resources to support this process.
DISCUSSION
Although our data reflect the perspectives of our respondents and may not be generalizable
to all IRB professionals, they offer important insights regarding the challenges that IRBs
may face as they address return of results. First is the knowledge and expertise required to
appropriately analyze these issues, especially in the context of a rapidly changing field
where unprecedented amounts of genomic and phenotypic data are gained and shared at an
extraordinary pace and the associations between these findings and disease development
may change just as quickly. Second, although return of individual research results is not a
new concept in clinical research—imaging studies have had a long history of revealing
incidental findings that are communicated to research subjects34, 35—return of results that
have clinical relevance from basic science studies, especially in genomic research, is a new
concern. For some of our respondents, the interview process itself provided one of the first
opportunities for in-depth analysis of this issue. Third, the increase in genomic studies that
IRBs anticipate reviewing in the future creates even more tension regarding how to address
the issue of returning research results. Finally and perhaps most important, is the lack of
national guidance on this issue upon which IRB professionals can anchor their decisions.
Neither the Common Rule nor current OHRP guidance address the issue of return of
individual research results.1, 32 Many respondents in our study were not comfortable
developing local policies in isolation. Even those IRBs who have some guidelines in place,
including the requirement to validate research results in a CLIA approved lab before return,
found that some real life situations precluded them from complying with their own rule.
However, despite these challenges and expressions of perplexity, respondents in our study
were very thoughtful in trying to integrate all legitimate perspectives on this issue, and
articulated many of the concerns previously described in the literature.1, 5, 9-20, 31 These
concerns reflected several dimensions of and individual thresholds for uncertainty, including
the broad scope of the science juxtaposed with the highly contextual nature of each ROR
scenario, and the challenges of appropriately assessing the analytical and clinical validity
and clinical utility of a particular research result. The concern of having an individual act on
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research results that may be incorrect or have low predictive power, or providing a research
result that predicts a condition that has no medical intervention, fueled many of the
uncertainties regarding how to appropriately assess potential risk and anticipated benefit.
However, our respondents were firm in their position that a research participant’s right to
know/ not know information about themselves be respected and they supported the return of
validated, medically actionable results. These positions are similar to those reported by
genetic researchers.22, 36 Two studies with genetic/genomic researchers, using survey and
qualitative methods, respectively, both identified clinical utility, respect for participants, and
minimizing harm to participants as the common reasons for determining whether to return
results.36, 22 Participants in the qualitative study also considered the IRB to be a main
authority to see out to ensure that rules were being adhered to before researchers took
action. 22 However, as our study demonstrates, this can be a challenge when IRBs are still in
the process of developing their own guidelines.
Only a few other studies have reported perspectives of IRBs on ROR.23,37 Lemke et al
conducted a survey study with members of a professional group overseeing human subjects
research where 78% agreed that an “ethical duty existed to return individual research results
that could affect a participant’s health or health care.”23 This view was also supported by the
respondents in our study, along with contextual variables, such as the type of disease in
question and the strength of the association of the result with disease development or
response to therapy. The contextual nature of the ROR scenario was further highlighted by
Wolf et al. in a study where IRB chairs were presented with a scenario in which banked
DNA was used in a research study to evaluate risk of Alzheimer’s disease.37 Nearly all IRB
chairs in Wolf’s study expressed a desire to have predefined criteria regarding returning
results.37 Although respondents in our study also wanted guidance on ROR, the type of
guidance differed among the individuals, some wanted more concrete guidelines, others
preferred ground rules or best practices to guide them.
We found that respondents often used similar terms in different ways or the same term to
encompass a general concept without defining or clarifying what that term meant. The lack
of a common nomenclature is a long standing problem in human subjects research,
especially in human specimen research and biobanking.38 In our study, the frequent use of
the terms validated or clinical significance without identifying the threshold for meeting
those descriptions can hinder communication and decision-making between IRBs,
researchers and research participants. Even in the research community, agreement is lacking
regarding what these terms mean and how to measure them consistently.1
We also learned new perspectives. First, many of our respondents expressed a need to
consider the meaning of a research result not only today, but also in the future. This concern
was described especially when the researcher is maintaining contact with the research
subject over time and is maintaining a registry or database of research results. The
implication was that researchers may have a long-term responsibility to their research
subjects to monitor the literature for the clinical relevance, validity and utility of stored
research results and communicate relevant information to the research subjects in the future.
In contrast to the NHLBI recommendations suggesting that researchers are only responsible
for ROR for the length of time of the study,18 our respondents did not put a time limit on the
responsibility for monitoring currently uncertain results for future relevance. Second, we
learned that IRB professionals have a range of views regarding whether the IRBs should
play an active role in decision-making about returning individual results. Some respondents
felt that the IRB should oversee the decision-making process, but not necessarily be a
decision-maker. Finally, although there was agreement that results should be returned to
individuals who want them, there was little mention about how to incorporate research
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participant’s views or definitions on what conditions would constitute personal or clinical
utility.
The most challenging tension for IRBs in regulating the return of individual research results,
however, may be how the practice blurs the line between research and clinical care.35, 39
IRBs are responsible for the ethical conduct of research, not the ethical conduct of clinical
care. Research is meant to benefit society, not the individual research subject. Yet, in our
study, and in society today, “a special power was associated with genomic information.”40
Our respondents expected that genomic or genetic studies would provide important clinical
information for the research participant. And therein lies the conflict. The expectation for
individual benefit is antithetical to the traditional concept of research. Addressing the return
of individual research results that may be acted upon by the research participant crosses the
boundary between research and clinical care. However, in our study and others, the
communication of information that may benefit the research subject may also be considered
part of the IRBs moral obligation in their role to protect research subjects.23 It is not
surprising that respondents expressed different views regarding the responsibility of the IRB
to be actively involved in deciding whether a research result should be returned to an
individual research subject. It is also not surprising that we lack national guidance.
Next steps: An IRB-researcher partnership
As IRBs are faced with real-life ROR situations, they will be forced to make decisions and
develop management plans. Ground rules (and the range of acceptable interpretations) will
need to be developed to address what conditions are either necessary or sufficient criteria for
return (e.g., should actionable but unvalidated results be returned and what constitutes
validity) and what situation trumps another. Although much effort is being devoted to the
development of national and international policies for disclosing the results of genomic
studies to research participants, there are opportunities at the local level to facilitate this
process. One is the development of a partnership between IRB professionals and genomic
researchers to approach the issue of return of results at their institution. Both IRB
professionals and genomic researchers could benefit from a collaborative approach to
addressing this issue, with each providing the necessary context and details to inform local
management plans. Most importantly, research participants and the local community could
also benefit from this partnership. The partnership could help assess local needs and develop
management plans to meet those needs (Table 4). Training exercises involving contextually-
based case scenarios could be developed to provide IRBs and researchers with practice in
collectively conducting risk/benefit analyses, and opportunities to understand each other’s
concerns in addressing this issue. Similarly, such exercises could provide opportunities to
develop a common nomenclature of relevant terms and examine the logistics, infrastructure
and resources needed to support ROR. The partnership could lead to the development of a
management plan that incorporates ways to address mutual concerns. In addition, the
naturally occurring experiments that IRBs conduct in their research oversight
responsibilities could be studied and analyzed, evaluating factors influencing development
of different ROR policies and procedures. Having IRB professionals and researchers
working together to address return of results at the local level can also inform development
of policy at the national level.
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Table 1
IRB perspectives on returning individual results to research participants
Concerns/Positions Quotation from transcripts
Complexity of inter-related
context dependent issues
[P3] “Oh that is a loaded [question] …But my guess is that it depends totally on the situation, it depends
on what disease you’re talking about, it depends on what are the ramifications of that disease, you know
how strong the data are. I mean how valid is it? I mean is it something that they’ve seen one time? So I
think all those things have to be taken into consideration and then an informed judgment made as to
what’s appropriate to share back with the subject and what’s not. What are the things that have been
established without a doubt clinically?… Then absolutely that stuff should be communicated back to the
subject. But we’re just now sort of getting into those areas and I don’t want to say a fishing expedition,
but you know it’s still more exploratory, and trying to figure out what the relevance of things are, then I
think you can do a disservice by frightening a subject by telling, giving them too much information,




[P4] “…it [genetic research] is the piece I have the greatest ignorance about. You know a lot of the other
stuff in IRB you can look up in a manual or in regulations or you’ve been taught about it, you understand
[it]. Genetics is something new. I don’t understand genetics, but I understand a bit why it’s very
important to human subjects,…I feel uncomfortable being able to recognize if a subject’s genetic rights
are being considered.”
IRB’s moral responsibility [P21] “And then the question has come up, what do you [the IRB] do if you uncover one of these [genes]
in somebody, do you have a duty to disclose?”
Right to know/right not to know [P19]“I think if the research subject wants to know, yes. So I think they should be asked, ‘Do you want to
know the result of this study?’ and if the answer is ‘Yes, I want to know,’ I think the answer is yes.”
Validity of result (analytic and
clinical)
[P15] “So I think we do have to have some idea of how robust [are] the assays or the method, how well
it’s performed in that particular laboratory, what their track record is. Maybe it should be repeated
someplace else or under a different circumstance, a different lab or using a different method before you
give out that answer.”
[P23] “It depends… if there is a well-established connection with the disease [of interest], the researcher
has a responsibility to provide that information. But if there is not any clarity between the relationship of
the test, the presence or absence of genetic markers and any disease, then that information shouldn’t be
given to the patient because it just confuses and confounds things.”
Absolute right to know [P16] “I think as a general ethical and moral principle, researchers should disclose information, and I
think it raises a serious question in my mind about the ethical nature of a study that informs patients that
‘We will not disclose information to you, even if it’s significant.”
Return mutation status not
interpretation
[P2] “So I don’t have a problem with the researchers telling the person, “You have this gene”. I have a
problem with researchers making conclusions based on that research [and communicating that to the
research subject since] …it is still research.”
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Table 2
Approaches for managing return of resultsa
A. At the time study is submitted to the Institutional Review Board (IRB) for review (researcher responsibility)
• Indicate intent to return or not in the informed consent and IRB application
• Ensure transparency in consent process so research subject understands what will and will not be returned
• Justify the rationale for returning or not returning results in consent process and IRB application
• If return is intended, give the research subject option to receive or not receive results as part of informed consent process and
document
• Consider the future meaning of a currently uncertain clinical finding
A. During the course of the study or after study completion (IRB/researcher responsibility)
• High quality of assay methodology and result interpretation
• Only results that have been validated in a Clinical Laboratory Improvement Act (CLIA) approved laboratory should be returned to a
research subject
• Only medical professionals (e.g., genetic counselors, medical geneticists) with appropriate expertise should return results
a
This table represents approaches or guidelines described by our respondents that are in place at their institutional IRB
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Table 3
Suggestions for Returning a Research Resulta
I. Two tiered process for decision-making:
Tier 1: Assess clinical significance: Convene an expert group consisting of investigators, clinicians, medical geneticists,
treating physicians, Institutional Review Board (IRB), and others to evaluate the clinical relevance and validity of the finding
(where analytic validity would involve a second sample evaluated in a Clinical Laboratory Improvement Act (CLIA)
laboratory by same or different method) and whether the result is medically actionable.
Tier 2: Assess psychosocial and moral implications: Convene an expert group consisting of genetic counselors, medical
geneticist, treating physician, psychologist/psychiatrist, IRB, and others to: 1. evaluate the psychological, social, emotional
implications of returning the result to the research subject and/or their family; 2. consider the personal meaning/utility of the
result for the research subject and/or their family; 3. consider the moral obligation of the IRB/researcher to return the result
If the evaluation of the two tiers support return, develop a process for communicating the result to the research subject
and/or family.
II. Communicating the research result:
• Determine if the research subject wants to know the result
• Research result communicated by a medical professional with expertise (e.g., genetic counselor, medical geneticist).
• Consider provision for follow up care/counseling
• Consider the resources, infrastructure and logistics needed to support the process
a
This table summarizes and synthesizes suggestions made by respondents to optimally manage return of individual results.
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Table 4
IRB -Researcher Partnership to Address Return of Individual Genomic Results (ROR)
Opportunities and Issues to Consider for IRBs and genomic researchers:
• Provide collaborative education for IRB members and genomic researchers, including principles of genomics research and ethical/
social/process implications of return
• Develop a common nomenclature of relevant terms
• Conduct ROR training using a spectrum of case-based scenarios
• Consider implications for local research participants, including implications for native or minority populations
• Conduct training in ROR risk/benefit analysis, including clinical and psychosocial assessment
• Consider logistics, infrastructure and resources needed for return of individual results
• Develop a management plan
• Implement and evaluate management plan
• Consider cross-site IRB-researcher partnerships and management plans
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